Publications
663 results found
Joshi K, Muhith A, Obeid M, et al., 2021, Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond, Lung Cancer, Vol: 156, Pages: 147-150, ISSN: 0169-5002
Durvalumab is the first approved adjuvant immunotherapy agent for patients with stage III NSCLC treated with concurrent chemoradiotherapy and is associated with improved overall survival. In order to minimise the number of hospital visits for patients receiving durvalumab during the COVID-19 pandemic we implemented 4-weekly (20 mg/kg) durvalumab in place of 2-weekly infusions at The Royal Marsden Hospital. We assessed the potential impact of the safety of a 4-weekly schedule in patients receiving adjuvant durvalumab. We carried out a retrospective study of 40 patients treated with 2-weekly and 4-weekly infusions of durvalumab prior to and during the COVID-19 pandemic. Clinical documentation was analysed from 216 consultations across 40 patients receiving 2-weekly durvalumab and 66 consultations of 14 patients who switched from 2-weekly to 4-weekly durvalumab during the COVID-19 pandemic. In patients receiving 2-weekly durvalumab, the rate of grade 3 and 4 toxicities was 15 % compared to 7% in patients receiving 4-weekly durvalumab. Pre-existing autoimmune disease was considered a risk factor for the development of grade 3 or 4 toxicities. We did not observe any difference in the rate of grade 1 and 2 toxicities between the two groups. Our findings support the use of 4-weekly durvalumab during the COVID-19 pandemic and beyond, obviating the need for 2-weekly face-to-face consultations and blood tests, relevant given the current pandemic and the need to re-structure cancer services to minimise patient hospital visits and exposure to SARS-CoV-2.
Adizie JB, Tweedie J, Khakwani A, et al., 2021, Biomarker testing for people with advanced lung cancer in England, JTO Clinical and Research Reports, Vol: 2, ISSN: 2666-3643
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.
Clark J, Murphy R, Dell E, et al., 2021, Pleomorphic lung carcinoma - a rare response to a rare tumour, Publisher: ELSEVIER IRELAND LTD, Pages: S76-S76, ISSN: 0169-5002
Milner-Watts C, Lyons H, Cui W, et al., 2021, Detection of tier 1 variants with circulating tumour (ct) DNA next generation sequencing (NGS) in UK non-small cell lung cancer (NSCLC) patients, Publisher: ELSEVIER IRELAND LTD, Pages: S28-S28, ISSN: 0169-5002
Ly F, Brambilla C, Rice A, et al., 2021, An audit of compliance with NOLCP in the GLH era, Publisher: ELSEVIER IRELAND LTD, Pages: S27-S27, ISSN: 0169-5002
Sandsund C, Cowan-Dickie S, Fautly A, et al., 2021, Treatment dose-delay due to an exercise induced creatinine kinase level elevation/raise in a man with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (aNSCLC) - a case report, Publisher: ELSEVIER IRELAND LTD, Pages: S75-S75, ISSN: 0169-5002
Cui W, Popat S, 2021, Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma, DRUGS, Vol: 81, Pages: 971-984, ISSN: 0012-6667
- Author Web Link
- Cite
- Citations: 2
McDonald F, Guckenberger M, Popat S, et al., 2021, HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours, Publisher: ELSEVIER IRELAND LTD, Pages: S70-S71, ISSN: 0169-5002
Miura S, Hsia T-C, Hung J-Y, et al., 2021, Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon <i>EGFR</i> mutations: A real-world cohort study (UpSwinG)., Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Passaro A, Mok T, Peters S, et al., 2021, Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations, JOURNAL OF THORACIC ONCOLOGY, Vol: 16, Pages: 764-773, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 93
Garcia Campelo MR, Lin HM, Zhu Y, et al., 2021, Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L), LUNG CANCER, Vol: 155, Pages: 68-77, ISSN: 0169-5002
Manickavasagar T, Yuan W, Carreira S, et al., 2021, HER3 expression and MEK activation in non-small-cell lung carcinoma, Lung Cancer Management, Vol: 10, Pages: 1-12, ISSN: 1758-1966
Aim: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. Materials & methods: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA). Results: HER3 was highly expressed in 42.2% of cases. ERBB3 copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. ERBB3 RNA expression levels were significantly correlated with MEK activity after adjusting for EGFR expression. Conclusion: HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling.
Bischoff H, Scherpereel A, Antonia S, et al., 2021, First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743, Publisher: GEORG THIEME VERLAG KG, Pages: S17-S17, ISSN: 0934-8387
Cui W, Milner-Watts C, Saith S, et al., 2021, Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19, Publisher: ELSEVIER SCIENCE INC, Pages: S795-S795, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 4
Miura S, Hsia T-C, Hung J-Y, et al., 2021, UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, Publisher: ELSEVIER SCIENCE INC, Pages: S776-S777, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 1
Cui W, Milner-Watts C, Lyons H, et al., 2021, Circulating tumour (ct) DNA next generation sequencing (NGS) in UK advanced non-small cell lung cancer (aNSCLC) patients (pts), Publisher: ELSEVIER SCIENCE INC, Pages: S787-S788, ISSN: 1556-0864
Collins DC, Sundar R, Constantinidou A, et al., 2021, Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease (vol 20, 1210, 2020), BMC Cancer, Vol: 21, Pages: 1-1, ISSN: 1471-2407
Popat S, Tanna N, Hartridge-Lambert S, et al., 2021, Nivolumab in Second Line Non-Small Cell Lung Cancer - Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057, Publisher: ELSEVIER SCIENCE INC, Pages: S637-S638, ISSN: 1556-0864
Besse B, Felip E, Kim ES, et al., 2021, AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion plus Advanced/Metastatic NSCLC, Publisher: ELSEVIER SCIENCE INC, Pages: S684-S684, ISSN: 1556-0864
Borghaei H, Besse B, Bardia A, et al., 2021, Trastuzumab Deruxtecan Plus Pembrolizumab in Advanced/Metastatic Breast or Non-Small Cell Lung Cancer: A Phase 1b Study, Publisher: ELSEVIER SCIENCE INC, Pages: S236-S236, ISSN: 1556-0864
Whisenant J, Wong S, Torri V, et al., 2021, COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT), Publisher: ELSEVIER SCIENCE INC, Pages: S297-S297, ISSN: 1556-0864
Popat S, 2021, Immunotherapy - Current State of Play (Concentrating on Current Data for First Line and Salvage Strategies), Publisher: ELSEVIER SCIENCE INC, Pages: S84-S84, ISSN: 1556-0864
Yang JC-H, Reckamp KL, Kim Y-C, et al., 2021, Efficacy and safety of rociletinib versus chemotherapy in patients with EGFR-mutated NSCLC: the results of TIGER-3, a phase 3 randomized study, JTO Clinical and Research Reports, Vol: 2, ISSN: 2666-3643
Introduction: The TIGER-3 (NCT02322281) study was initiated to compare the efficacy and safety of rociletinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR T790M and common EGFR-activating mutations, versus chemotherapy in patients with NSCLC who progressed on first- or second-generation EGFR TKIs. Methods: Patients with advanced or metastatic EGFR-mutated NSCLC with disease progression on standard therapy (previous EGFR TKI and platinum-based chemotherapy) were randomized to oral rociletinib (500 or 625 mg twice daily) or single-agent chemotherapy (pemetrexed, gemcitabine, docetaxel, or paclitaxel). Results: Enrollment was halted when rociletinib development was discontinued in 2016. Of 149 enrolled patients, 75 were randomized to rociletinib (n = 53: 500 mg twice daily; n = 22: 625 mg twice daily) and 74 to chemotherapy. The median investigator-assessed progression-free survival (PFS) was 4.1 months (95% confidence interval [CI]: 2.6-5.4) in the rociletinib 500-mg group and 5.5 months (95% CI: 1.8-8.1) in the 625-mg group versus 2.5 months (95% CI: 1.4-2.9) in the chemotherapy group. An improved PFS was observed in patients with T790M-positive NSCLC treated with rociletinib (n = 25; 500 mg and 625 mg twice daily) versus chemotherapy (n = 20; 6.8 versus 2.7 mo; hazard ratio = 0.55, 95% CI: 0.28-1.07, p = 0.074). Grade 3 or higher hyperglycemia (24.0%), corrected QT prolongation (6.7%), diarrhea (2.7%), and vomiting (1.3%) were more frequent with rociletinib than chemotherapy (0%, 0%, 1.4%, and 0%, respectively). Conclusions: Rociletinib had a more favorable median PFS versus chemotherapy but had higher rates of hyperglycemia and corrected QT prolongation in patients with advanced EGFR-mutated NSCLC who progressed on previous EGFR TKI. Incomplete enrollment prevented evaluation of the primary efficacy end point.
Chang W-C, Zhang YZ, Wolf JL, et al., 2021, Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases, 108th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) - Unlocking Your Ingenuity, Publisher: WILEY, Pages: 434-444, ISSN: 0309-0167
- Author Web Link
- Cite
- Citations: 12
Baas P, Scherpereel A, Nowak AK, et al., 2021, First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, LANCET, Vol: 397, Pages: 375-386, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 486
Popat S, Sharma B, MacMahon S, et al., 2021, Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment, JCO PRECISION ONCOLOGY, Vol: 5, Pages: 39-43
- Author Web Link
- Cite
- Citations: 4
Lee R, Girard N, Popat S, 2021, Molecular Targetable Pathways – EGFR, Encyclopedia of Respiratory Medicine, Second Edition, Pages: 844-852, ISBN: 9780081027233
The Epidermal Growth Factor Receptor (EGFR or ‘HER1’), is a tyrosine kinase receptor which upon acquisition of distinct driver mutations within the kinase domain (e.g. L858R or deletion in exon 19) becomes constitutively activated driving abnormal cell replication. EGFR is one of the most important targets for kinase inhibition in non-small cell lung cancer, and therefore serve as a critical biomarker for targeted therapy. Notably EGFR mutations are commonest in young, never-smoking, Asian women with lung adenocarcinoma. The evolution of more recent generations of EGFR inhibitors has served to target acquired resistance driven by evolution of mutations such as T790M. This chapter first describes the genetic and molecular significance of EGFR before presenting the contexts in which targeted inhibition of the EGFR pathway is used clinically.
Coakley M, Popat S, 2021, Molecular Targetable Pathways—ALK, Encyclopedia of Respiratory Medicine, Second Edition, Pages: 853-864, ISBN: 9780081027233
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase which becomes oncogenic and drives tumor growth in multiple tumor types, including non-small cell lung cancer (NSCLC). We discuss the pathophysiology of ALK in NSCLC, which is driven predominantly by ALK gene rearrangements. We review the various methods of molecular testing for ALK gene rearrangements in NSCLC, and their limitations. Oral Tyrosine Kinase Inhibitors (TKIs) targeting the ALK pathway have been rapidly developed in the past 10 years. These drugs are well tolerated and offer prolonged disease control. We highlight the most up-to-date clinical data for each of the agents currently available which target the ALK pathway, and discuss adverse events associated with each agent. We discuss mechanisms of resistance to the ALK-targeted TKIs, and options for treatment at disease progression.
Yang JC-H, Schuler M, Popat S, et al., 2021, Afatinib in Asian and Non-Asian Patients (pts) with EGFR Mutation-Positive (EGFRm plus ) NSCLC Harboring Major Uncommon Mutations, Publisher: ELSEVIER SCIENCE INC, Pages: S31-S31, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 1
Popat S, Kim HR, Ahn M-J, et al., 2021, Systemic and Intracranial Efficacy of Brigatinib vs.Crizotinib: Updated Results from the ALTA-1L Trial, Publisher: ELSEVIER SCIENCE INC, Pages: S8-S9, ISSN: 1556-0864
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.